Lay summary
New Zealand has one of the highest rates of Staphylococcus aureus bacteraemia (SAB - bloodstream infection) in the world. Māori and Pacific people are particularly affected. The mortality of SAB is 15-20%. Good evidence for the best SAB treatment is lacking and international guidelines reflect this uncertainty. Variation in SAB treatment is associated with mortality. We propose a novel platform trial to answer multiple questions about SAB treatment simultaneously. As an intervention is shown to be preferable, it becomes the standard of care and new interventions can be trialled against it. In this way we hope to find treatments that save lives, reduce morbidity, and save money, all using cheap and familiar antibiotics.